GARFIELD-AF Registry

GARFIELD-AF registry

GARFIELD-AF was the largest prospective registry of patients with newly diagnosed atrial fibrillation

Back to GARFIELD-AF
Keep Up to Date Login
Menu
  • Home

      • The TRI team continues to publish papers based on data accrued during the study (#50 was published in April 2021). Click on a branch of the tree to access the papers associated with that area.

        • Burden of Disease
        • Risk Stratification
        • Treatment Practices
        • Therapy Persistence
        • Clinical Outcomes
        • Geographic Differences
        • Health Economics
  • About
    • About GARFIELD-AF
    • Our Governance
    • About Atrial Fibrillation
    • External Links
  • Risk Calculator
  • Publications & Presentations
  • Newsletters
  • Media
  • Community Page

Clinical Outcomes

This section analyses clinical outcomes in patients with AF, specifically looking at 30,000 patients with 2-year outcomes data

Key Data:

  • Two-year outcomes data from GARFIELD-AF show that death is the most frequent adverse outcome for patients with AF
    • The highest rates of stroke/systemic embolism, major bleeding and death occurred during the first 4 months of follow-up and gradually diminished over time
    • Anticoagulation therapy was associated with a 35% lower risk of death
    • Strokes were not the most frequent cause of mortality, accounting for less than 10% of all known causes of death
    • Mortality rate due to cardiovascular (CV) causes including fatal bleeds was 1.55 per 100 person-years. CV deaths were most frequently caused by CHF, sudden or unwitnessed death, ACS and ischaemic stroke
      • Strokes accounted for fewer than 10% of all known causes of death
    • Mortality rate due to non-CV causes was lower, at 1.37 per 100 person-years. Non-CV deaths were most frequently caused by malignancy, respiratory failure and infection/sepsis
    • Strokes were predominantly ischaemic and primary haemorrhagic strokes were very uncommon
    • Bleeding events most frequently occurred in the gastrointestinal tract (1.5% of the total registry population)

Key Publications:

Related Publications

Click to view publications related to Clinical Outcomes... [read more]

16 Jun 21
Previous Page

Community members, please login to view additional information

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Follow-up
Study end: 2018

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

info@tri-london.ac.uk Contact Us

Follow Us

Keep up to date

Sign up to our newsletter to receive news and updates from us

Keep Up to Date

Funding

The GARFIELD-AF registry was funded by an unrestricted research grant from Bayer AG, and the ongoing work is supported by the Thrombosis Research Institute.

© Copyright TRI 2023

All Rights Reserved. No part of this site may be reproduced without our permission.

  • About TRI
  • Cookie Notice
  • Privacy Policy
  • Terms of Use

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup




    Please see our Privacy Policy and Cookie Policy

    Contact Us

      To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

      E: garfield@tri-london.ac.uk
      T: 0203 198 9947